TickerTalks
Browse all tickers →
TickerTalks›$PACB
PAPACB

Pacific Biosciences of California, Inc.

$PACB·$538M·Medical - Devices·Healthcare
$1.73-11.7%YTD+5.1%1Y-1.7%
Price updated 8h ago·X counts updated 5d ago
PAPACB
$PACBPacific Biosciences of California, Inc.
$1.73-11.73%235 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PACB on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

235X posts · last 7 days
Sep 29Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $PACB's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 53% of tracked names.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PACB — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

Gene-sequencing name running near its 52-week highs with elevated volume and losses that are no longer widening.

PACB is a long-read DNA-sequencing company whose stock has nearly doubled over the trailing year and sits in the top sliver of its 52-week range, with volume running at well over double the 30-day baseline — the technical signature of a crowded, high-beta name back in favor. The fundamentals are the opposite of settled: the business still loses money, revenue is roughly flat year-on-year, and free cash flow is deeply negative. What has changed is the direction of the EPS surprise column, where recent quarters have printed meaningfully narrower losses than consensus expected.

  • Trailing-year return in the mid-to-high 70s with YTD return in the low 30s; price near the top of the 52-week band
  • High beta relative to the market and volume multiplier running at roughly 2.4x the 30-day baseline — a crowded tape
  • Revenue roughly flat year-on-year across the latest two quarters; operating margin still deeply negative; free cash flow negative in the latest print
  • Last two quarters beat consensus on EPS by double-digit percentages even while still reporting losses
  • Next earnings in early November, with the analyst estimate pointing to a slightly narrower loss again

Momentum is doing the work and the beats are feeding it, but the equity has not yet shown profitability or a clear inflection in top line. The November print is where that gap closes in one direction or the other.

What to watch: The November earnings release — specifically whether revenue growth returns to positive territory, where cash burn stands relative to the balance sheet, and any instrument placement or consumables commentary.

On the calendar: 2026-11-03 earnings

high betaunprofitableno sentiment

Read the AI verdict on $PACB

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Devices sits in its cycle right now — and what that implies for $PACB.

Medical - Devices · Healthcare

Aging population demographics and AI-assisted device adoption (smart implants, continuous glucose monitors, digital health integration) are the long-cycle structural drivers. Reimbursement timing for new modalities (CMS coverage decisions) and procedure volume recovery from COVID-era deferred care shape the 2026 revenue trajectory.

Industry benchmark

21-name peer basket
+9.8%YTD
+0.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-5.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-23.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-102%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-23.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-49.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
36.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-21.3Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 3, 2026$-0.14$-0.13-9.4%
Q1 2026May 7, 2026$-0.03$-0.17+82.4%
Q4 2025Feb 12, 2026$-0.12$-0.19+36.8%
Q3 2025Nov 5, 2025$-0.12$-0.16+25.0%
Next earningsTue, Nov 3·consensus EPS $-0.13

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$39.0M-1.9%32.4%-114%$-0.14$-84.9M
Q1 FY26$37.2M+0.1%34.5%-102%$-0.03$-47.7M
Q4 FY25$44.6M+13.8%37.5%-92.3%$-0.13$-19.9M
Q3 FY25$38.4M-3.8%39.2%-101%$-0.13$-18.6M

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$158.8M$156.0M – $161.7M-$0.46-$0.48 – -$0.434
FY27$183.0M$178.7M – $187.4M-$0.45-$0.48 – -$0.435
FY28$212.5M$203.9M – $221.3M-$0.36-$0.41 – -$0.276
FY29$242.3M$232.0M – $252.3M-$0.26-$0.27 – -$0.244
FY30$276.9M$265.2M – $288.4M-$0.21-$0.22 – -$0.203

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.28%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+8.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+8.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 304.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.195-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellOct 6James R GibsonSee Remarks661.8K sh$2.1MSellAug 17Van Oene MarkSee Remarks26.9K sh$30K
+ 10 other (9 awards · 1 exempt) in window

See when $PACB insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KRestructuring / exit costsAug 58-K — Item 2.02: Earnings release · Item 2.05: Restructuring / exit costs · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Pacific Biosciences of California, Inc. (PACB) filed an 8-K on 2026-08-05 disclosing a director or executive officer departure, appointment, or compensation change (Item 5.02). No narrative detail was available in the excerpt; this is typically an administrative personnel or governance disclosure with limited market impact unless it involves a key C-suite role.

8-KOfficer or director changeJul 98-K — Item 5.02: Officer or director change
8-KOfficer or director changeJun 48-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 10 other (3 proxys · 2 10-Qs · 1 13G · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investorszacks.com·2d agoPacBio to Report Third Quarter 2026 Financial Results on November 4, 2026globenewswire.com·3d agoPacBio Teams With TychoBio to Advance AI-Driven RNA Therapeuticszacks.com·4d agoPacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s Whydefenseworld.net·5d agoInsider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $2,058,244.65 in Stockdefenseworld.net·6d ago

More in Medical - Devices

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TMDX$MDT$QSI$BIO$ABT$BSX$BFLY$GEHC
Voices on X · last 7 days

No standout posts about $PACB on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport